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A B S T R A C T 
Background: Egyptian hospital–based statistics showed that head & neck carcinomas 
represent 18% of all cancers and mostly diagnosed at advanced stages. Our Clinical 
Oncology & Nuclear Medicine Department of Mansoura Faculty of Medicine serves a 
large rural area of the Delta region of Egypt. There is no previous study in our 
institution that focused on oral tongue carcinoma alone. This study aims in establishing 
the demographics, treatment outcome and prognostic factors of oral tongue squamous 
cell carcinoma (SCC). 
Methods: We retrospectively reviewed data of 50 cases with oral tongue SCC treated in 
our department from January 2014 to December 2016 to evaluate the demography, 
pathological characteristics, and therapeutic modalities. We estimated the survival 
rates during the entire follow-up period by the Kaplan–Meier method. The univariate 
and multivariate Cox proportional hazards analysis were performed for prognostic 
factors determination. 
 
Results: The median follow-up was 30 months (range: 4-45 months). The 3-year overall 
survival (OS) and disease-free survival (DFS) rates were 68% and 60% respectively.  By 
univariate analysis, both advanced stages (III, IVA) and depth of invasion >0.5 cm were 
statistically significant as prognostic factors for 3-year DFS and OS rates. DFS rates were 
34% vs. 98% for stage III and IVA vs. stage I and II respectively (p = 0.001); 52% vs. 78% 
for >0.5 cm vs.  ≤0.5 cm depth of invasion (p = 0.003). OS rates were 36% vs. 99% for 
stage III and IVA vs. stage I and II respectively (p = 0.002); 52% vs. 80% for >0.5 cm vs.  
≤0.5 cm depth of invasion (p = 0.001). Multivariate analysis of prognostic factors 
affecting 3-year DFS and OS rates confirmed the statistical significance of the same 2 
factors. 
 
Conclusions: The majority of our patients were males below 60 years. Tumors were 
mainly found at stage III and were moderately differentiated. Vascular invasion and 
lymphatic permeation were uncommon. Staging and tumor invasion depth significantly 
affected the outcome. The 3-year OS and DFS were 68% and 60% respectively.      
 
 
 
INTRODUCTION 
 
In the Middle East, smoking rates are considerable. 
Egyptian hospital–based statistics showed that head & 
neck carcinomas represent 18% of all cancers and 
mostly were diagnosed at advanced stages (1). A report 
of the Middle-East Cancer Consortium of the National 
Cancer Institute in Bethesda, USA, reported that Egypt 
has one of the highest rates of such tumors in the 
Middle East (2). The Nile Delta of Egypt is the region 
where the Nile River spreads out and drains into the 
Mediterranean Sea. It extends between Alexandria in 
the West to Port Said in the East and it is a rural 
agricultural region with poor access to dentists. Our 
Clinical Oncology and Nuclear Medicine Department is 
one of the main oncology centres in Nile Delta of Egypt. 
As no studies concerning oral tongue squamous cell 
carcinoma (SCC) have been published in our institution, 
this study aimed at exploring the clinico-epidemiological 
features of the disease as well as the prognostic factors.       
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METHODS 
We retrospectively reviewed the database from 
January 2014 to December 2016. Inclusion criteria 
included oral tongue SCC patients. However, exclusion 
criteria were: patients with other malignancies, poor 
performance status (Eastern Cooperative Oncology 
Group (ECOG) ≥ 3), end-stage renal disease, Child-Pugh 
C liver cirrhosis, or poor heart or lung function and 
lastly, patients with missing data about their staging. 
The data were obtained from Clinical Oncology & 
Nuclear Medicine Department database. Data collection 
was authorized by our institutional Ethical Committee 
(Code R.18.01.20.R1-2018/04/14). 
Patient characteristics that were considered 
included: age, gender, staging, histological grade, 
pathologic descriptions and treatment modalities. 
Staging was according to the 7th edition of the 
American Joint Committee on Cancer staging (3). 
Treatment modalities that were applied by different 
physicians and documented in the records were 
performed according to the National Comprehensive 
Cancer Network Guidelines. The technique of 
delineation for conformal radiotherapy was according to 
the Radiation Therapy Oncology Group Guidelines. 
Following the treatment, patients were subjected to 
regular follow-up. Follow-up was in the form of clinical 
examination plus magnetic resonance imaging or 
computerized tomography scan of head and neck every 
3 months in the first year, every 6 months in the second 
year, yearly in the third year and then every 2 years till 
death.  
Generally, in cases of documented relapse or disease 
persistence, the patient was reassessed by a 
multidisciplinary treatment board to decide the suitable 
salvage treatment. Death was considered to be related 
to tongue cancer if it was documented in the file or it 
occurred within one month after the treatment ends. 
Descriptive analysis was performed to characterize 
the patient’s demographic variables, pathological 
characteristics and therapeutic modalities by reporting 
them as frequencies and proportions. The follow-up 
periods for each patient was calculated from treatment 
end date until the date of death or last follow up. 
Disease-free survival was calculated from treatment 
start date to the date of recurrence. Overall survival was 
calculated from date of diagnosis to date of death or 
last follow up. We estimated the survival rates during 
the entire follow-up period by the Kaplan–Meier 
method. The univariate and multivariate Cox 
proportional hazards analysis was performed for 
prognostic factors that influence survival. For all tests, 
significance was defined at p<0.05.The statistics were 
accomplished through Statistical Package Version 16 
(SPSS, INC., Chicago, IL, USA). 
 
RESULTS 
 
Table 1. Patients, tumor, and treatment characteristics 
Characteristics N (%) 
Age (years)   
 ≤ 60 45 (90%) 
 > 60 5 (10% 
Gender 
 
 
Male 30 (60%) 
Female 20 (40%) 
Performance status 
 
 
ECOG 0 12 (24%) 
 
ECOG 1 38 (76%) 
T-category  
 T1 5 (10%) 
 T2 9 (18%) 
 T3 35 (70%) 
 T4a 1 (2%) 
N-category  
 N0 32 (64%) 
 N1 13 (26%) 
 N2 5 (10%) 
 N3 0 (0%) 
Stage  
 I 1 (2%) 
 II 10 (20%) 
 III 38 (76%) 
 IVA 1 (2%) 
Histological grade  
 Low grade 16 (32%) 
 Moderately grade 22 (44%) 
 High grade 12 (24%) 
Depth of invasion (cm)  
 ≤ 0.5 28 (56%) 
 > 0.5 22 (44%) 
Resection margin  
 Negative 49 (98%) 
 Close (< 0.5 cm) 1 (2%) 
 Positive 0 (0%) 
Lymphovascular invasion  
 Yes 3 (6%) 
 No 47 (94%) 
Perineural invasion  
 Yes 4 (8%) 
 No 46 (92%) 
Surgery of primary site  
 Simple excision 4 (8%) 
 Wide excision 8 (16%) 
 Hemiglossectomy 38 (76%) 
Neck dissection  
 Yes 38 (76%) 
 No 12 (24%) 
Radiotherapy  
 Yes 38 (76%) 
 No 12 (24%) 
Concurrent chemotherapy  
 Yes 28 (56%) 
 No 22 (44%) 
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Patients, tumor, and treatment characteristics 
Patient, tumor, and treatment characteristics of 50 
cases of SCC of the oral tongue are shown in Table 1. 
The age was ranged from 40 to 72 years old (mean: 52 
years ± 12.3), 45 (90%) patients were ≤ 60 years and 5 
(10%) patients were > 60 years. There were 30 (60%) 
males and 20 (40%) females. Thirty-eight (76%) patients 
had ECOG 1 performance status. Smoking habit was 
documented in 20 (40%) patients, while documentation 
of delayed diagnosis because of lack of dentists’ 
awareness was documented in 3 cases.  There were 38 
(76%) patients with clinical stage III. Pathologic 
specimens were assessed. Twenty-two patients (44%) 
patients had moderately differentiated disease and 28 
(56%) patients had disease with depth of invasion ≤ 0.5 
cm. 
Among the total of 50 patients, 4 (8%) patients 
underwent simple excision, 8 (16%) patients underwent 
wide excision while hemiglossectomy was performed in 
38 (76%) patients. Neck node dissection was performed 
in 38 (76%) patients. Thirty eight patients (76%) 
received radiotherapy with the median dose of 62.7Gy 
to the primary tumor, 60.1Gy to positive neck node, and 
45Gy to electively treated neck node. All patients 
received 3-dimensional conformal radiation therapy. 
Weekly concurrent chemotherapy was administrated in 
28 (56%) of patients (26 cases received cisplatin and 2 
cases received carboplatin). Range of chemotherapy 
weekly cycles was 2 to 6 cycles (median was 3 cycles). 
Patterns of failure 
Recurrence was reported in 20 cases which include 
10 local failures, 8 regional failures, and 4 distant 
metastases. Locoregional failure occurred in 18 patients. 
There were 16 (32%) patients with locoregional failure 
in stage III, 1 (2%) patient in stage II, and 1 (2%) patient 
in stage IVA. 
Local failure was reported in 1 (2%) patient with T2, 
8 (16%) patients with T3 and 1 (2%) patient T4a disease. 
Salvage surgical resection was done in 30% (3 out of 10) 
of patients who had local failure, while 7 patients did 
not undergo operation due to locally unresectable 
disease in 2 patients and 5 patients refused surgical 
resection. Eight patients reported regional failure: One 
(2%) patient with N0, 1 (2%) patient with N1, and 6 
(12%) patients with N2. Two patients had salvage neck 
dissection, while 4 patients declined the surgery, and 2 
had distant metastases. 
Distant metastases (lung metastases) were reported 
in 4 patients. Chemotherapy was received and tolerated 
by 2 patients with distant metastases (1 patient 
received cisplatin + 5-fluorouracil and the other one 
received carboplatin + paclitaxel). 
 
Survival and prognostic analysis 
The median follow-up was 30 months (range: 4-45 
months). A total of 16 patients died. Causes of death 
were due to tongue cancer in 10 patents, cardiac event 
in 1 patient, end stage renal disease in 1 patient, and 
unknown cause in 4 patients. The median OS was 41 
months. The 3-year OS and DFS were 68% and 60% 
respectively (figure 1 and 2). 
By univariate analysis (Table 2.), both advanced 
stages (III and IVA) and depth of invasion > 0.5 cm were 
statistically significant prognostic factors for 3-year DFS 
and OS rates. DFS rates were 34% vs. 98% for stage III 
and IVA vs. stage I and II respectively (p = 0.001); 52% 
vs. 78% for >0.5 cm vs.  ≤0.5 cm depth of invasion (p = 
0.003). OS rates were 36% vs. 99% for stage III and IVA 
vs. stage I and II respectively (p = 0.002); 52% vs. 80% 
for >0.5 cm vs. ≤0.5 cm depth of invasion (p = 0.001). 
Multivariate analysis of prognostic factors affecting 3-
year DFS and OS rates revealed the statistical 
significance of the 2 factors (Table 3). 
 
 
Figure 1. Disease-free survival of 50 patients with SCC of oral 
tongue 
 
 
Figure 2. Overall survival of 50 patients with SCC of oral 
tongue 
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Table 2. Univariate analysis of prognostic factors affecting DFS and OS 
Variable 3-year DFS (%) HR (95%CI)  p-value 3-year OS (%) HR (95%CI)  p-value 
Age  
    ≤ 60  
    > 60 
 
64 
56 
 
1.83 
(0.94-1.92) 
 
0.96 
 
64 
56 
 
2.19 
(0.45-9.65) 
 
0.98 
Gender 
    Male  
    Female 
 
58 
62 
 
3.07 
(0.98–8.7) 
 
0.65 
 
60 
62 
 
4.99 
(0.95-10.65) 
 
0.32 
Performance status 
    ECOG 0  
    ECOG 1 
 
66 
54 
 
2.83 
(0.45-20.65) 
 
0.98 
 
66 
56 
 
4.19 
(0.85-11.05) 
 
0.43 
T-category 
    T1,T2 
    T3, T4a 
 
58 
30 
 
1.07 
(0.89–8.7) 
 
0.67 
 
59 
31 
 
3.19 
(0.45-9.75) 
 
0.65 
N-category 
    N0  
    N +ve 
 
66 
54 
 
3.11 
(0.08–8.32) 
 
0.3 
 
68 
56 
 
3.99 
(0.95-7.65) 
 
0.34 
Stage 
     I, II  
     III, IVA 
 
98 
34 
 
3.09 
(1.02–7.33) 
 
0.001 
 
99 
36 
 
3.39 
(1.95-9.25) 
 
0.002 
Histological grade 
   Low, Intermediate grade 
   High grade 
 
62 
44 
 
2.63 
(0.45-10.65) 
 
0.7 
 
64 
40 
 
2.87 
(0.45-10.65) 
 
0.42 
Depth of invasion 
    ≤ 0.5  
    >0.5              
 
78 
52 
 
3.73 
(2.45-12.65) 
 
0.003 
 
80 
52 
 
4.19 
(1.45-11.65) 
 
0.001 
Resection margin 
   Negative  
   Close, Positive 
 
64 
31 
 
1.83 
(0.84-1.92) 
 
0.97 
 
66 
34 
 
2.19 
(0.45-9.65) 
 
0.87 
Lymphovascular Invasion 
   Yes  
   No 
 
44 
66 
 
2.07 
(0.98–8.2) 
 
 
0.43 
 
46 
68 
 
4.99 
(0.95-10.65) 
 
 
0.63 
Perineural invasion 
   Yes  
   No 
 
46 
62 
 
3.83 
(0.45-9.65) 
 
0.65 
 
46 
66 
 
4.19 
(0.85-11.05) 
 
0.85 
Surgery of primary site 
   Simple excision  
   Wide excision,  Hemiglossectomy 
 
54 
69 
 
2.07 
(0.89–3.7) 
 
0.43 
 
54 
71 
 
5.19 
(0.45-9.75) 
 
0.93 
Neck dissection 
   Yes  
   No 
 
62 
56 
 
2.11 
(0.08–5.32) 
 
0.46 
 
64 
58 
 
3.99 
(0.95-9.65) 
 
0.76 
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Radiotherapy 
   Yes  
   No 
 
62 
58 
 
4.83 
(0.94-11.92) 
 
0.43 
 
68 
58 
 
2.15 
(0.45-5.65) 
 
0.23 
Chemotherapy 
   Yes  
   No 
 
68 
52 
 
3.44 
(0.98–8.7) 
 
0.32 
 
70 
52 
 
1.99 
(0.95-2.65) 
 
0.32 
 
Table 2. Multivariate analysis of prognostic factors affecting DFS and OS 
OS DFS Variable 
p-value (95%CI) HR p-value (95%CI) HR  
0.004 (1.45-9.65) 3.99 0.001 (3.45-20.65) 7.09 Stage ( I,II Vs. III, IVA) 
0.01 (1.45-11.65) 4.19 0.01 (3.45-20.65) 3.83 Depth of invasion (≤ 0.5 Vs. >0.5)         
 
DISCUSSION 
In Africa, the incidence rate of oral carcinomas is 
2.6/100.000 people and the rate is higher in males. 
Male to female ratio is 3,3:2 (4). In India, the incidence 
is one of the highest in the world due to the popularity 
of betel and areca nuts with male to female ratio of 
2,3:1 (5).  In USA the incidence is 1,6-2,9/100.000 (6 ). In 
England, as a European example, the yearly mean 
incidence is 1,4/100.000  population with male to 
female ratio of 1,6:1 (7). 
In our institution, the incidence of tongue cancer 
was 50% of oral cavity carcinomas but less than 1% of all 
cancers received during the study period. The functions 
of tongue as regard mastication, swallowing, taste and 
speech are very much affecting quality of life but 
unfortunately, the access to optimum oral health care is 
limited in rural areas. Consequently, this work aimed at 
exploring the clinic –epidemiological characteristics of 
oral tongue SCC which was not studied before in our 
institution.   
The role of tobacco in development of oral cavity 
carcinomas is well documented (8). Smoking habit was 
documented in the records of 20 patients in this study 
(40%). Unfortunately, tobacco awareness programs are 
still deficient especially in rural areas with existence of 
wrong beliefs about the positive correlation between 
smoking habit and personal prestige.   
The mean age in the present study was 52±12 years 
similar to the large Indian study (124 patients) of Shukla 
et al. (50±12) (9). No ages below 20 years old was 
recorded in our study and this parallels with the 
published fact of paucity of these patients worldwide 
(10). In our study, males exceeded females. This result 
agrees with results of other publications in different 
parts of the world as the American paper of Tota et al. 
(11), the Spanish paper of Garcia-Kass et al. (12), 
Dhanuthai et al. (13) from Thailand and the Turkish 
study of Duzlu et al. (14).  
Stages III & IV represented more than two thirds of 
our cases similar to a large Brazilian population-based 
study (15) and a respectable Japanese report (16). This 
observation is really strange because tongue is an 
accessible organ. Population in our rural areas cannot 
afford the high cost of dental care since   very few of 
them are covered by insurance. As a result, they rarely 
seek the advice of dentists. Unfortunately, the exact 
role for dentists in the disease scenario of each of our 
patients, if any, was not documented in all the records. 
However, it was frankly   reported that delayed 
diagnosis of the cancer in 3 of our cases was due to 
deficiency in the dentists’ knowledge. This agrees with 
the interesting review of Stoykova (17). Increasing 
awareness of dentists about oral carcinomas can help 
detecting oral carcinomas at earlier stages. 
Surgery alone is the treatment of early stage tongue 
carcinoma. Adjuvant therapy is used when pathologic 
adverse features exist (18). Multidisciplinary treatment 
in the form of surgery, external radiotherapy, and 
chemotherapy was the main focus of our institutional 
policy in treating tongue cancer especially in advanced 
stages. High dose brachytherapy was proven to be 
beneficial for control in T1 tumor (19). However, it was 
not among our treatment policies due to unavailability. 
Similarly, neo adjuvant chemotherapy was reported to 
give favorable results (20, 21) and so was the retrograde 
super selective intra-arterial chemo radiotherapy (22). 
These techniques have not yet been investigated in our 
department. 
Our 3-year overall survival figure seems similar to 
other publications like the  respectable paper of Spiotto 
et al. (23) who studied 2803 cases. Their 3-year overall 
survival was from 67%-73%. However, the 3-year overall 
survival rate of Mroueh et al. (24) from Finland who 
studied 360 patients was 80%.This may be attributed to 
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the very high socioeconomic standard in Finland. The 
non-satisfactory survival rates of tongue cancer make 
identification of early serum markers for tumor 
detection, such as N-glycopeptides, urgent (25). 
Regarding the prognostic factors, age was not 
among our prognostic factors. However, Jeon et al. (26) 
concluded in his study of 117 patients that tongue 
cancer prognosis in ages less than 40 years is worse 
than those above 40 years. On the other hand, Tsai et 
al. (27) reported that ages above 75 years had worse 
survival rate in the group of advanced stage. In our 
study, patients above 60 years were just 5 in number so 
we could not test the effect of very advanced age on 
prognosis. Staging and depth of invasion were proven to 
be our independent statistically significant prognostic 
factors. This parallels with the results of Cariati et al. 
(117 cases) (28). However, extra nodal extension, nerve 
and vascular invasion were other significant factors 
reported by Cariati and his group. Depth of invasion was 
of prognostic significance in other several studies as that 
of Tarsitano et al. (67 patients) (29) and Hori et al. (48 
patients) (30). Inclusion of the depth of invasion in the 
recent 8th version of TNM Classification of the AJCC was 
worthy as clarified by Almangush et al. (31). 
Determination of the tumor depth has a significant 
aspect other than the prognosis. Intraoral sonography 
applied before surgery to determine the depth leads to 
minimizing the chance of occurrence of surgical margin 
positivity as clarified by the respectable review of Klein 
Nulent et al. (32). Intraoral sonography has not yet been 
applied in the routine preoperative policy of tongue 
cancer management in our institution. Cassidy et al. (33) 
studied 180 N0 tongue cancers and found that 
lymphatic permeation is of poor prognostic impact and 
consequently he highlighted the need to include it 
among the indications of adjuvant radiotherapy in 
radically resected N0 tongue cancer. Pathologic grading 
in the present work was of no prognostic significance. 
Dik et al. (34) in his study that included 145 early oral 
squamous cell carcinoma (mainly tongue carcinomas) 
patients reported a similar observation. The limited 
independent prognostic factors in the present study 
may be due to the limited number of patients. 
The retrospective nature of the study with missing of 
some data beside the small patient number represents 
limitations of the study.  
 
CONCLUSIONS 
 
The majority of patients of our institution were 
males below 60 years with stage III moderately 
differentiated tumors. Vascular invasion and lymphatic 
permeation were uncommon. Tumor staging and tumor 
invasion depth significantly affected the outcome. The 
3-year OS and DFS were 68% and 60% respectively. 
Tobacco awareness programs and periodic oral 
examination by well-trained dentists could help in early 
detection of tongue carcinoma. 
 
ACKNOWLEDGEMENT 
We have to acknowledge all of our institutional IT team 
for their cooperation 
 
DECLARATIONS 
 
Ethical approval 
This study was approved by the ethical committee of 
Faculty of Medicine, Mansoura University. 
 
Competing of Interest 
The authors declare that they have no competing 
interests. 
 
REFERENCES 
1. Attar E1, Dey S, Hablas A, Seifeldin IA, Ramadan M, 
Rozek LS, Soliman AS  Head and neck cancer in a 
developing country: a population-based perspective 
across 8 years Oral Oncol. 2010 Aug;46(8):591-96. 
2. Freedman LS, Edwards BK, Ries LAG, Young JL. Cancer 
incidence in four member countries (Cyprus, Egypt, 
Israel, and Jordan) of the Middle East cancer consortium 
(MECC) compared with US SEER. 2006. 
3. Edge SB, Compton CC. The American Joint Committee on 
Cancer: the 7th edition of the AJCC cancer staging 
manual and the future of TNM. Annals of Surgical 
Oncology. 2010;17:1471–74. 
4. All Cancers (excluding non-melanoma skin cancer) 
estimated incidence, mortality and prevalence 
worldwide in 2012". International Agency for Research 
on Cancer. 201.2 
5. Mallath, Mohandas K; Taylor, David G; Badwe, Rajendra 
A; Rath, Goura K; Shanta, V; Pramesh, C S; et al  (May 
2014). "The growing burden of cancer in India: 
epidemiology and social context". The Lancet Oncology. 
15 (6): e205–e212.  
6. Reichman ME1, Kelly JJ, Kosary CL, Coughlin SS, Jim MA, 
Lanier AP. Incidence of cancers of the oral cavity and 
pharynx among American Indians and Alaska Natives, 
1999-2004 Cancer. 2008 Sep 1;113(5 Suppl):1256-65.  
7. Olaleye O, Ekrikpo U, Lyne O, Wiseberg J. Shield KD, 
Ferlay J, et al. Incidence and survival trends of lip, intra-
oral cavity and tongue base cancers in south-east 
England. Ann R Coll Surg Engl. 2015 Apr;97(3):229-34. 
8.  Kataki AC, Sharma JD, Krishnatreya M, Baishya N, Kalita 
M.  Patterns of tobacco use in patients with upper aero 
digestive tract cancers: A hospital-based study. J Cancer 
Res Ther. 2018 Jan-Mar;14(2):437-40. 
9. Shukla NK, Deo SVS, Garg PK, Manjunath NML, Bhaskar 
S, Sreenivas V .Operable oral tongue squamous cell 
cancer: 15 Years Experience at a tertiary care center in 
North India .Indian J Surg Oncol. 2018 Mar;9(1):15-23  
10. Sharma D, Singh G.Pediatric head and neck squamous 
cell carcinoma: A retrospective observational 
study.Indian J Cancer. 2016 Jul-Sep;53(3):397-98.  
108 |   Squamous cell carcinoma of the oral tongue: A cohort study from Mansoura University Hospital 
 
 
 
www.indonesianjournalofcancer.or.id 
ARTICLE IN PRESS 
11. Tota JE, Anderson WF, Coffey C, Califano J, Cozen W, Ferris 
RL,et al.   Rising incidence of oral tongue cancer among 
white men and women in the United States, 1973-2012.     
Oral Oncol. 2017 Apr;67:146-52. 
12. García-Kass AI1, Herrero-Sánchez A, Esparza-Gómez G.    
Oral tongue cancer in public hospitals in Madrid, Spain 
(1990-2008). Med Oral Patol Oral Cir Bucal. 2016 Nov 
1;21(6):e658-64. 
13. Dhanuthai K, Rojanawatsirivej S, Thosaporn W, Kintarak S, 
Subarnbhesaj A, Darling M, et al. Oral cancer: A 
multicenter study. Med Oral Patol Oral Cir Bucal. 2018 Jan 
1;23(1):e23-9 
14. Düzlü M, Karamert R, Bakkal FK, Cevizci R, Tutar H, Zorlu 
ME,et al.  The demographics and histopathological 
features of oral cavity cancers in Turkey. Turk J Med Sci. 
2016 Dec 20;46(6):1672-76. 
15. Cohen Goldemberg D, de Araújo LHL, Antunes HS, de Melo 
AC,    Santos Thuler LC     Tongue cancer epidemiology in 
Brazil: incidence, morbidity and mortality.Head Neck. 2018 
Aug;40(8):1834-44. 
16. Shibahara T     Oral cancer -diagnosis and therapy.Clin 
Calcium. 2017;27(10):1427-33. 
17. Stoykova M   Delayed diagnosis of cancer with emphasis 
on oral cavity cancers. Folia Med (Plovdiv). 
1999;41(1):132-35. 
18. Katz O, Nachalon Y, Hilly O, Shpitzer T, Bachar G, Limon 
D,et al.  Radiotherapy in early-stage tongue squamous cell 
carcinoma with minor adverse features.Head Neck. 2017 
Jan;39(1):147-50. 
19. Potharaju M, E HR, Muthukumaran M, Venkataraman M, 
Ilangovan B, Kuppusamy S   Long-term outcome of high-
dose-rate brachytherapy and perioperative brachytherapy 
in early mobile tongue cancer    J Contemp Brachytherapy. 
2018 Feb;10(1):64-72. 
20. Kina S, Nakasone T, Kinjo T, Nimura F, Sunagawa N, Arasaki 
A et al.   Outcomes after up-front surgery and metronomic 
neoadjuvant chemotherapy with S-1 or UFT for early 
tongue squamous cell carcinoma.Clin Oral Investig. 2018 
Oct 13; doi: 10.1007/s00784-018-2689.- 
21. Sadighi S, Keyhani A, Harirchi I, Garajei A, Aghili M, 
Kazemian A,et al. Neoadjuvant chemotherapy for locally 
advanced squamous carcinoma of oral cavity: a Pilot 
StudyActa Med Iran. 2015;53(6):380-86. 
22. Mitsudo K, Hayashi Y, Minamiyama S, Ohashi N, Iida M, 
Iwai T, et al.  Chemoradiotherapy using retrograde 
superselective intra-arterial infusion for tongue cancer: 
Analysis of therapeutic results in 118 cases.Oral Oncol. 
2018 Apr;79:71-7.  
23. Spiotto MT, Jefferson GD, Wenig B, Markiewicz MR, 
Weichselbaum RR, Koshy M   Survival outcomes for 
postoperative chemoradiation in intermediate-risk oral 
tongue cancers.Head Neck. 2017 Dec;39(12):2537-48.  
24. Mroueh R, Haapaniemi A, Grénman R, Laranne J, Pukkila 
M, Almangush A, et al.    Improved outcomes with oral 
tongue squamous cell carcinoma in Finland.Head Neck. 
2017 Jul;39(7):1306-12. 
25. Saraswat M, Mäkitie A, Tohmola T, Dickinson A, Saraswat 
S, Joenväärä S, et al.   Tongue cancer patients can be 
distinguished from healthy controls by specific N-
Glycopeptides found in serum.Proteomics Clin Appl. 2018 
Jul 11;e1800061.PMID: 29992770. 
26. Jeon JH, Kim MG, Park JY, Lee JH, Kim MJ, Myoung H, et al.   
Analysis of the outcome of young age tongue squamous 
cell carcinoma.Maxillofac Plast Reconstr Surg. 2017 Dec 
25;39(1):41-5 
27. Ming-Shao Tsai,, Chia-Hsuan Lai, Chuan-Pin Lee, Yao-Hsu 
Yang Pau-Chung Chen, Chung-Jan Kang, et al Mortality in 
tongue cancer patients treated by curative surgery: a 
retrospective cohort study from CGRD PeerJ. 2016; 4: 
e2794.Published online 2016 Dec 15.PMCID: PMC5162395 
28. Cariati P, Cabello Serrano A, Fernandez Solis J, Martinez 
Lara  Distribution of cervical metastasis in tongue cancer: 
Are occult metastases predictable? A retrospective study 
of 117 oral tongue carcinomas. J Craniomaxillofac Surg. 
2018 Jan;46(1):155-61. 
29. Tarsitano A, Del Corso G, Tardio ML, Marchetti CTumori 
Infiltration depth as predictor of nodal metastasis in early 
tongue squamous cell carcinoma.J Oral Maxillofac Surg. 
2016 Mar;74(3):523-27. 
30. Hori Y, Kubota A, Yokose T, Furukawa M, Matsushita T, 
Takita M,et al.    Predictive significance of tumor depth and 
budding forlate lymph node metastases in patients with 
clinical N0 early oral tongue carcinoma. Head Neck Pathol. 
2017 Dec;11(4):477-86.. 
31. Almangush A, Leivo I, Siponen M, Sundquist E, Mroueh R, 
Mäkitie AA, et al. Evaluation of the budding and depth of 
invasion (BD) model in oral tongue cancer biopsies 
Virchows Arch. 2018 Feb;472(2):231-36.  
32. Klein Nulent TJW, Noorlag R, Van Cann EM, Pameijer FA, 
Willems SM, Yesuratnam A, et al. Intraoral 
ultrasonography to measure tumor thickness of oral 
cancer: A systematic review and meta-analysis .Oral Oncol. 
2018 Feb;77:29-36. 
33. Cassidy RJ, Switchenko JM, Jegadeesh N, Sayan M, Ferris 
MJ, Eaton BR, et al  . Association of lymphovascular space 
invasion with locoregional failure and survival in patients 
with node-negative oral tongue cancers. JAMA Otolaryngol 
Head Neck Surg. 2017 Apr 1;143(4):382-88. 
34. Dik EA, Ipenburg NA, Kessler PA, van Es RJJ, Willems SM. 
The value of histological grading of biopsy and resection 
specimens in early stage oral squamous cell carcinomas.J 
Craniomaxillofac Surg. 2018 Jun;46(6):1001-06.
 
 
 
